Cetuximab

Findings presented at ASCO Quality Care Symposium provided new insights into the effects last year’s cisplatin shortage had on patients with head and neck cancer.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

In this video, Nihkil Munshi, MD, Professor of Medicine at Harvard Medical School, discusses the proliferation of new drugs to treat multiple myeloma and how they have changed the standard of care for the disease.

The FDA announced several regulatory actions the past few weeks.

The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.

Carboplatin-based systemic therapy appeared associated with longer survival than cetuximab among patients with head and neck squamous cell carcinoma ineligible for cisplatin, according to study results.

Adagrasib alone and in combination with cetuximab exhibited promising efficacy compared with historical outcomes among heavily pretreated patients with advanced colorectal cancer who had KRASG12C mutations.

A phase 3 study of monalizumab among patients with squamous cell carcinoma of the head and neck will be discontinued after a futility interim analysis failed to meet a predefined threshold for efficacy, according to a press release.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the STRATEGIC-1 trial, which she said validates a common initial treatment strategy for patients with RAS and BRAF wild-type metastatic colorectal cancer.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.